2CUREX

2cureX AB

Healthcare · SEK · STO

2CUREX

Price

SEK 1.772

+2.19%

Cap

SEK 45.54M

Earnings

30d Trend

-15.6%

2CUREX
Loading chart data...
0 days · % change from startPowered by Brain47
VolatilityHigh

161% annualised over 90 days

BRAIN47 SIGNAL

0
MODERATE
Risk Level85
Quality22
Momentum81
Technical62
Fundamentals20

Raw weighted: 48×Macro 0.99 (1%)=48

RISK

85/100
90d Volatility
161.2%High
ATR %
9.6%High daily moves
Max Drawdown (1Y)
-90.4%Volatile

QUALITY

22/100
ROE (avg)
-97.3%*Negative
Piotroski F-Score
2/9Weak
Accruals
0.0%Accrual heavy

MOMENTUM

81/100
6-1M Momentum
+41.9%Positive
1M Return
-9.1%Recent pullback

TECHNICAL

62/100
RSI (14)
49.7Neutral
Price vs SMA200
+9.4%Bullish trend
MACD
-0.04Bearish momentum
Bollinger Band
30%Mid-range
SMA Cross
Golden CrossGolden Cross
Trend Quality (KER)
0.148Noisy/choppy

FUNDAMENTALS

20/100
Shareholder Yield
0.0%Low

Macro: neutral (×0.99) - Fear/Greed: 64 (Greed) - Data: 100%

Running historical backtest...

BRAIN47 HORIZON ANALYSIS

<3 months41
3-12 months79
1-5+ years20

6-9 month momentum thesis — strong trend with confirmation

BRAIN47'S ASSESSMENT

I rate 2cureX AB at 48/100 — a MODERATE reading on the Brain47 Signal. The strongest factor is momentum at 81/100. I classify this as a speculative position with the strongest thesis on a medium-term horizon.

PAST PERFORMANCE

1 MONTH

-9.1%

3 MONTHS

+10.4%

12 MONTHS

Trailing returns — past performance, not a projection.

DETAILED ANALYSIS

6-9 month momentum thesis — strong trend with confirmation. Momentum (81) and Technical (62) are the primary strengths. I note an elevated risk profile — this warrants closer monitoring. Historical volatility is elevated at 161%. I classify this as a speculative position — elevated volatility at 161% and smaller market cap define the opportunity.

speculativeScore: 48/100

Want full analysis on every stock?

Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.

Join Brain47 — Free

Generated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.